The Quinze-Vingts Hospital and GenSight Biologics announce a first Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France

38th Annual J.P. Morgan Healthcare Conference, San Francisco (CA), USA

GenSight Biologics Reports its Cash Position as of September 30, 2019 and Provides Operational Update

GenSight Biologics Appoints Magali Taiel as Chief Medical Officer

GenSight Biologics integrates the Enternext® PEA-PME 150 index by Euronext

Future is now: Leaders in Ocular Gene Therapy Meeting, San Francisco (CA)

GenSight Biologics Reports Interim Financial Results for the First Half of 2019 and Provides Operational Update

GenSight Biologics expands its Board of Directors with the appointments of Maritza McIntyre and Sofinnova Partners

Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude

GenSight Biologics to Host KOL Breakfast on May 23, 2019 in New York